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low-up schedule are still unknown. We are currently conducting Phase 
I/II study for RFA for thoracic malignancy using FDG-PET-CT as an 
evaluation procedure. Here we report the result of our study and useful-
ness of FDG-PET-CT scan as an evaluation procedure after RFA.
Method: In the last two years, we performed RFA on 11 patients who 
had thoracic malignancy. We evaluated 9 patients out of 11 who had 
positive FDG accumulation to tumors in this study. They were 8 males 
and 1 female with a mean age of 75.2 years (range of 65-81years old). 
Two patients had primary lung cancer, 4 patients had recurrent lung 
cancer, 3 patients had metastatic tumor. Tumor size were 0.8-2.5cm in 
diameters (mean: 1.64cm). All patients were not candidate to surgery 
because of their cardiac or pulmonary dysfunctions and underwent CT-
guided percutaneous RFA under local anesthesia.
Result: No mortality and no major morbidity were noted. Morbidity 
was observed 5 cases out of 9 patients (55.6%) included 3 patients with 
pneumothorax without drainage, 1 patient who had chest pain dur-
ing ablation and 1 patient who had fever without any treatment after 
RFA. Obvious decrease of FDG accumulation was observed in early 
examination (7-14days) after RFA in 8 patients out of 9, only 1 patient 
showed stable accumulation of FDG.
After ‚S-16months (mean follow up period were 9.75M) follow up 
periods, those 8 patients had no clear local recurrence. 
Conclusion: RFA for thoracic malignancy seems to be safe and fea-
sible. Early examinations of FDG-PET-CT scan after RFA may be use-
ful for evaluation of a local control. To clarify the effectiveness of RFA 
on patients’ survival, it still is needed that larger series clinical trial and 
much longer observation. 
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Background: An EAP was developed for the use of pemetrexed (P) in 
patients with MPM before and during review by regulatory agencies. 
Previous studies showed promising results for the use of single-agent 
P or the combination of P+platinum for chemonaive pts with MPM. 
The phase II study (Scagliotti 2003) of P showed a response rate (RR) 
of 14.1% (95% CI 6.6, 25.0), time to progressive disease (TtPD) of 4.7 
mos (95% CI 4.2, 5.8), and median survival time of 10.7 mos (95% 
CI 7.7, 14.5), with a 1-yr survival rate of 47.8%. The phase III study 
of P+cisplatin (Cis) versus Cis in MPM demonstrated a signiﬁcantly 
different RR (41.3% vs 16.7% p<0.001), TtPD (5.7 mos vs 3.9 mos, 
p=0.001), and survival beneﬁt (median survival: 12.1 mos vs 9.3 mos, 
p=0.020; 1-yr survival: 50.3% vs 38.0%, p=0.012) in favor of P+Cis 
(Vogelzang 2003). The EAP provided access to P alone or P plus Cis or 
carboplatin (Cb) for 3312 pts in 13 countries. Safety and efﬁcacy data 
for chemonaïve pts receiving P or P+platinum are summarized in this 
abstract.
Methods: Eligible pts had histologic or cytologic diagnosis of MPM 
not amenable to curative surgery. P 500 mg/m2 alone or in combination 
with either Cis 75 mg/m2 or Cb AUC 5 was given on day 1 of each 21-
day cycle, with standard premedication consisting of vitamin B12, folic 
acid, and dexamethasone. Investigator-determined best response (RR) 
and survival data (with censoring) were recorded at the end of study 
participation. Myelosuppression data (NCI CTC, version 2.0) were also 
collected.
Results: In this nonrandomized, open-label study 2023 chemonaïve 
pts received ≥ 1 dose of P (319 pts), P+Cis (843 pts) or P+Cb (861 
pts) and were evaluable for safety. Of the study participants, 247 P pts, 
745 P+Cis pts, and 752 P+Cb pts were evaluable for efﬁcacy. Baseline 
characteristics, and efﬁcacy and safety data are summarized in the 
table.
Conclusions: In this large, nonrandomized study, all three treatment 
arms (P, P+Cis, and P+Cb) had clinically similar one-year survival 
rates, whereas the combination arms had higher response rates than 
P alone. These results conﬁrm the efﬁcacy of P or P+platinum in the 
treatment of chemonaive pts with MPM. 
 P P+Cis P+Cb
Median age (years) (range) 69 (39-87) 62 (24-78) 66 (35-89)
Male (%) 78.1 85.3 80.5
Karnofsky performance status ≥ 80, 
% of pts* 71.6 86.8 85.8
RR, % of pts (95% CI) 10.5 (7. 0, 15.0) 26.3 (23.2, 29.6) 21.7 (18.8, 24.8)
Disease control rate (responders 
+SD), % of pts (95% CI) 59.1 (52.7, 65.3) 77.7 (74.6, 80.7) 75.8 (72.6, 78.8)
One-year survival rate, % (95% CI) 58.6 (43.4, 73.8) 63.1 (50.7, 75.5) 64.0 (53.3, 74.6)
Median TtPD (months) (95% CI) 6.0 (4.6, 7.2) 7.0 ( 6.7, 8.3) 6.9 (6.6, 7.7)
Leukopenia, Gr 3/4, % of pts 14.7 13.1 21.0
Neutropenia, Gr 3/4, % of pts 17.3 23.9 36.1
Thrombocytopenia, Gr 3/4, % of pts 2.9 5.0 14.3
Anemia, Gr 3/4, % of pts 7.5 7.2 14.3
* >90% of pts in each treatment arm were assessed for performance status.
